ArticleFrontiers in oncology2025
Venetoclax as a cytoreduction therapy option for acute promyelocytic leukemia in newly diagnosed adult patients: a case report of a 35-year-old female with schizophrenia.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Venetoclax is effective in treating relapsed acute promyelocytic leukemia (APL), newly diagnosed pediatric APL, variant APL, and APL with central nervous system involvement. In newly diagnosed adult APL, venetoclax is rarely used. Herein, we present a case of newly diagnosed adult APL in a 35-year-old female with schizophrenia who received venetoclax as a cytoreduction therapy option. The patient was admitted with myocardial ischemia, the cardiac ultrasound indicating left ventricular ejection fractions (EF) of 44%, a 17-year history of schizophrenia, treated with ziprasidone, lorazepam, and clozapine. She developed differentiation syndrome (DS) shortly after receiving All-trans-retinoic acid (ATRA) and arsenic trioxide (ATO) and experienced heart arrest. In the occurrence of DS, this young female encountered numerous therapeutic conundrums, including cytoreduction of hydroxyurea being ineffective, the potential psychological worsening caused by dexamethasone use, and the cardiotoxicity of anthracyclines. We administered venetoclax 20 mg once daily as a cytoreduction therapy. The white blood cells (WBC) dropped from 72.16×10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.